Symbols / CCXI
CCXI Chart
About
No company description available for this symbol.
Fundamentals
Scroll to Statements| Sector | — | Industry | — | Market Cap | — |
| Enterprise Value | — | Income | — | Sales | — |
| Book/sh | -0.00 | Cash/sh | — | Dividend Yield | — |
| Payout | — | Employees | — | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | — | P/B | -3380.00 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | — |
| Current Ratio | — | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | — | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | — | ROA | — |
| ROE | — | ROIC | — | Gross Margin | — |
| Oper. Margin | — | Profit Margin | — | Shs Outstand | — |
| Shs Float | — | Short Float | — | Short Ratio | — |
| Short Interest | — | 52W High | 10.45 | 52W Low | 10.07 |
| Beta | — | Avg Volume | 6.96K | Volume | 22.33K |
| Target Price | — | Recom | None | Prev Close | $10.18 |
| Price | $10.14 | Change | -0.39% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$10.14
Latest analyst target
3. DCF / Fair value
—
Simplified FCF or EPS-based estimate
Ratings
Current target
$10.14
Low
—
High
—
Mean
—
- ChemoCentryx's (CCXI) Stock Increases on Tavneos' FDA Nod - Nasdaq Mon, 27 Dec 2021 08
- Why ChemoCentryx Stock Plunged 79% in May - The Motley Fool Fri, 04 Jun 2021 07
- ChemoCentryx Stock More Than Doubles On $4B Buyout - Yahoo Finance hu, 04 Aug 2022 07
- ChemoCentryx Up Most Since 2019 on Autoimmune Drug Approval - Bloomberg.com Fri, 08 Oct 2021 07
- Amgen to Acquire ChemoCentryx for $3.7B, Bolstering Autoimmune Portfolio - GEN - Genetic Engineering and Biotechnology News Fri, 05 Aug 2022 07
- ChemoCentryx Shares Are Spiking After an Unexpected FDA Approval - Barron's Fri, 08 Oct 2021 07
- Why ChemoCentryx Stock Crashed Today - Nasdaq ue, 04 May 2021 07
- Churchill Capital Corp X (CCCX) Stock News on Dec. 24, 2025: Infleqtion Quantum SPAC Deal, Latest Catalysts, and What Comes Next - TechStock² Wed, 24 Dec 2025 08
- Why ChemoCentryx Stock Tanked in 2021 - The Motley Fool Wed, 12 Jan 2022 08
- ChemoCentryx (CCXI) Tavneos Gets EU Nod for ANCA Vasculitis - Nasdaq hu, 20 Jan 2022 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 19898 | 1013793.0 | — | Sale at price 50.95 per share. | KANAYA SUSAN M | Chief Financial Officer | — | 2022-08-16 00:00:00 | D |
| 1 | 19898 | 216092.0 | — | Conversion of Exercise of derivative security at price 10.86 per share. | KANAYA SUSAN M | Chief Financial Officer | — | 2022-08-16 00:00:00 | D |
| 2 | 10000 | 502200.0 | — | Sale at price 50.22 per share. | TYREE JAMES L | Director | — | 2022-08-04 00:00:00 | D |
| 3 | 46298 | 2322715.0 | — | Sale at price 50.17 per share. | KANAYA SUSAN M | Chief Financial Officer | — | 2022-08-04 00:00:00 | D |
| 4 | 46298 | 300805.0 | — | Conversion of Exercise of derivative security at price 6.23 - 6.62 per share. | KANAYA SUSAN M | Chief Financial Officer | — | 2022-08-04 00:00:00 | D |
| 5 | 130000 | 6531733.0 | — | Sale at price 50.24 per share. | SCHALL THOMAS J | Chief Executive Officer | — | 2022-08-04 00:00:00 | D |
| 6 | 130000 | 1856400.0 | — | Conversion of Exercise of derivative security at price 14.28 per share. | SCHALL THOMAS J | Chief Executive Officer | — | 2022-08-04 00:00:00 | D |
| 7 | 7564 | 379864.0 | — | Sale at price 50.22 per share. | CAPPEL MARKUS J | Officer and Treasurer | — | 2022-08-04 00:00:00 | D |
| 8 | 17237 | — | — | Stock Award(Grant) at price 0.00 per share. | HERRON JENNIFER LYN | Director | — | 2022-06-28 00:00:00 | D |
| 9 | 3863 | 99129.0 | — | Sale at price 25.65 - 26.22 per share. | TYREE JAMES L | Director | — | 2022-06-09 00:00:00 | D |
Financials
No financial statements available. Data is sourced from Yahoo Finance and cached; historical storage may be added later.
Public Trades for CCXI
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|